Treats major depressive disorder (MDD). ANDA 204065, held by Actavis Laboratories FL. Desvenlafaxine Succinate.
As of Nov 22, 2026, ANDA 204065 (Desvenlafaxine Succinate), held by Actavis Laboratories FL, was first approved by FDA on Jul 29, 2016, with 4 approved supplements and 0 published complete response letters.
Desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (MDD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 29, 2016 | Original application | Approved | None posted |
| Desvenlafaxine SuccinateEQ 25MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 50MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 100MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Aug 16, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 16, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 29, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters